Lisaftoclax (APG-2575)

DRUG4 trials

Sponsors

Ascentage Pharma Group Inc., Ruijin Hospital

Conditions

CLL/SLLHigher-risk Myelodysplastic SyndromeMantle Cell Lymphoma (MCL)Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia

Phase 1

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

RecruitingNCT04501120

Ascentage Pharma Group Inc.Myeloid Malignancy, Relapsed/Refractory Acute Myeloid Leukaemia

Start: 2020-09-28End: 2029-09-30Target: 458Updated: 2025-09-26

Phase 2

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

RecruitingNCT07272499

Ruijin HospitalMantle Cell Lymphoma (MCL)

Start: 2025-09-10End: 2028-09-10Target: 25Updated: 2025-12-09

Phase 3

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

RecruitingNCT06319456

Ascentage Pharma Group Inc.CLL/SLL

Start: 2024-04-07End: 2028-08-31Target: 344Updated: 2024-05-29

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

RecruitingNCT06641414

Ascentage Pharma Group Inc.Higher-risk Myelodysplastic Syndrome

Start: 2025-01-22End: 2029-12-31Target: 490Updated: 2025-11-20

Related Papers

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Blood2024-11-051 citations

Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia.

Journal of Clinical Oncology2024-06-012 citations

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Blood2023-11-023 citations